Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906)

Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906) - Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003393

Enrollment

Registered

2010-03-29

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-squamous non-small cell lung cancer without EGFR Mutation

Interventions

Pemetrexed 500mg/m2 day1 + Carboplatin AUC6 day1, q3w, 3-6 cycles

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven non-squamous non small cell lung cancer 2) Patients with EGFR wild type 3) Patients with stage IIIB or IV, or recurrent disease after surgery and was not a candidate for curative radiotherapy 4) No prior chemotherapy 5) Patient who has measurable lesion by RECIST 6) Age: 20-74 7) ECOG PS: 0-1 8) Adequate organ function 9) Life expectancy more than 3 months 10) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Active infection 2) Fever 3) Serious disease condition 4) Active double cancer 5) Symptomatic brain metastasis 6) Cavity fluid retention difficult to control 7) Severe drug allergy 8) Pregnancy or lactation 9) Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Adverse events Disease control rate Overall survival Progression free survival	—

Countries

Japan

Contacts

Public ContactTomoki Kimura

Tosei General Hospital Respiratory medicine and allergy

lung@tosei.or.jp0561-82-5101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026